In the BioHarmony Drug Report Database

"Preview" Icon

Levofloxacin

Iquix, Levaquin, Quixin, Quinsair (levofloxacin) is a small molecule pharmaceutical. Levofloxacin was first approved as Iquix on 1996-12-20. It is used to treat bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bronchitis amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections. Levofloxacin’s patent is valid until 2022-02-26 (FDA).

 

Trade Name

 

Quinsair
 

Common Name

 

levofloxacin
 

ChEMBL ID

 

CHEMBL33
 

Indication

 

bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, chlamydia infections, cystic fibrosis, escherichia coli infections, haemophilus infections, klebsiella infections, legionnaires' disease, maxillary sinusitis, mycoplasma infections, proteus infections, protozoan infections, pseudomonas infections, pulmonary tuberculosis, pyelonephritis, respiratory tract infections, salmonella infections, soft tissue infections, staphylococcal infections, streptococcal infections, urinary tract infections
 

Drug Class

 

Antibacterials (quinolone derivatives)

Image (chem structure or protein)

Levofloxacin structure rendering